Abiopharma

🔍 Tatnall Christopher (Executive)

Company: AXCELIS TECHNOLOGIES INC (ACLS)

Report Date: 2026-04-20

Detailed Transactions and Holdings:

• Sold 907 shares of Common Stock at $131.02 per share (Direct)
  Date: 2026-04-20 | Code: F | equity_swap_involved: 0 | shares_owned_after: 23,044.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3

Footnotes:

• F1: This forfeiture of shares for tax withholding purposes relates to the vesting on April 18, 2026 of service vesting restricted stock units granted to the executive in April 2022. The shares issued to the executive on the vesting were reduced by a number of shares having a value equal to the executive's tax withholding obligation with respect to the vested restricted stock units.
• F2: Represents the closing price of the Company's common stock on the date of the tax withholding.
• F3: Of the shares held after this vesting on April 18, 2026, 16,463 were issuable on vesting of restricted stock units granted to the reporting person under the 2012 Equity Incentive Plan and are subject to forfeiture. This amount includes restricted stock units earned by the reporting person upon the achievement of 112.5% of the restricted stock units granted in 2025 based upon the achievement of 2025 performance goals.